Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus
This study assessed whether Helicobacter pylori infection could influence metformin tolerance in patients with type 2 diabetes mellitus. Demographic, anthropometric, ultrasound, and laboratory data were obtained from 415 metformin-naive patients with diabetes. H. pylori infection was assessed based...
Gespeichert in:
| Veröffentlicht in: | Diabetes technology & therapeutics 2015-02, Vol.17 (2), p.128-133 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 133 |
|---|---|
| container_issue | 2 |
| container_start_page | 128 |
| container_title | Diabetes technology & therapeutics |
| container_volume | 17 |
| creator | Huang, Yuxin Sun, Jiao Wang, Xingsi Tao, Xiaoming Wang, Haidong Tan, Wen |
| description | This study assessed whether Helicobacter pylori infection could influence metformin tolerance in patients with type 2 diabetes mellitus.
Demographic, anthropometric, ultrasound, and laboratory data were obtained from 415 metformin-naive patients with diabetes. H. pylori infection was assessed based on the (13)C-labeled urea breath test ((13)C-UBT). The study duration was 4 weeks, and all subjects started metformin from 500 mg/day to 1,500 mg/day progressively. Gastrointestinal side effects were assessed each week, and the metformin doses were adjusted by the compliance. Gastrointestinal side effects were compared between H. pylori-positive and -negative groups.
According to the (13)C-UBT results, 220 patients were categorized as H. pylori negative versus 195 as H. pylori positive. At baseline, the scoring of gastrointestinal symptoms showed no statistical difference between the two groups. After 4 weeks, for gastrointestinal symptoms such as abdominal pain, nausea, bloating, and anorexia, the respective percentages in H. pylori-positive and -negative subjects were 44.6% versus 21.8% (P < 0.01), 20.0% versus 9.6% (P < 0.01), 47.7% versus 23.2% (P < 0.01), and 32.8% versus 12.3% (P < 0.01). The final metformin dose was 951.28 ± 661.1 mg in H. pylori-positive subjects, significantly less than that in H. pylori-negative subjects (1,209.09 ± 522.91 mg) (P < 0.01). On multivariate analysis, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol were the independent parameters associated with any gastrointestinal symptoms.
Patients with diabetes having H. pylori infection demonstrated more gastrointestinal side effects than those without H. pylori infection after taking metformin. Furthermore, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol are independent determinants of metformin's side effects. |
| doi_str_mv | 10.1089/dia.2014.0203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652462061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652462061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-836663709f8ff834f809d05c628ac74971ac41c1228d885833053c34456697d93</originalsourceid><addsrcrecordid>eNpdkD2P1TAQRS0EYj-gpEWWaGjymLFjxy7RCtiVVqKB2vJzJsKrJA62I_T-PX7sQkE1U5y5OnMZe4NwQDD2wxj9QQD2BxAgn7FLVGrojLLy-XkX0FlU-oJdlfIAAIMU-JJdCCUtAtpLRrc0x5COPlTKfDvNKUce14lCjWnlI4VMvlDhC9Up5SWuvKaZsl8DNY5vvkZaa-G_Yv3B62kjLnhzOlL9czTPse7lFXsx-bnQ66d5zb5__vTt5ra7__rl7ubjfReaV-2M1FrLAexkpsnIfjJgR1BBC-PD0NsBfegxoBBmNEYZKUHJIPteaW2H0cpr9v4xd8vp506luiWW0CT8SmkvDrUSvRagsaHv_kMf0p7XZudwMGZAVBYa1T1SIadSMk1uy3Hx-eQQ3Ll_13515_7duf_Gv31K3Y8Ljf_ov4XL37o5f5E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1788711590</pqid></control><display><type>article</type><title>Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Huang, Yuxin ; Sun, Jiao ; Wang, Xingsi ; Tao, Xiaoming ; Wang, Haidong ; Tan, Wen</creator><creatorcontrib>Huang, Yuxin ; Sun, Jiao ; Wang, Xingsi ; Tao, Xiaoming ; Wang, Haidong ; Tan, Wen</creatorcontrib><description>This study assessed whether Helicobacter pylori infection could influence metformin tolerance in patients with type 2 diabetes mellitus.
Demographic, anthropometric, ultrasound, and laboratory data were obtained from 415 metformin-naive patients with diabetes. H. pylori infection was assessed based on the (13)C-labeled urea breath test ((13)C-UBT). The study duration was 4 weeks, and all subjects started metformin from 500 mg/day to 1,500 mg/day progressively. Gastrointestinal side effects were assessed each week, and the metformin doses were adjusted by the compliance. Gastrointestinal side effects were compared between H. pylori-positive and -negative groups.
According to the (13)C-UBT results, 220 patients were categorized as H. pylori negative versus 195 as H. pylori positive. At baseline, the scoring of gastrointestinal symptoms showed no statistical difference between the two groups. After 4 weeks, for gastrointestinal symptoms such as abdominal pain, nausea, bloating, and anorexia, the respective percentages in H. pylori-positive and -negative subjects were 44.6% versus 21.8% (P < 0.01), 20.0% versus 9.6% (P < 0.01), 47.7% versus 23.2% (P < 0.01), and 32.8% versus 12.3% (P < 0.01). The final metformin dose was 951.28 ± 661.1 mg in H. pylori-positive subjects, significantly less than that in H. pylori-negative subjects (1,209.09 ± 522.91 mg) (P < 0.01). On multivariate analysis, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol were the independent parameters associated with any gastrointestinal symptoms.
Patients with diabetes having H. pylori infection demonstrated more gastrointestinal side effects than those without H. pylori infection after taking metformin. Furthermore, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol are independent determinants of metformin's side effects.</description><identifier>ISSN: 1520-9156</identifier><identifier>EISSN: 1557-8593</identifier><identifier>DOI: 10.1089/dia.2014.0203</identifier><identifier>PMID: 25391019</identifier><identifier>CODEN: DTTHFH</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Body mass index ; Breath Tests ; China - epidemiology ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; Female ; Gastrointestinal Tract - drug effects ; Helicobacter Infections - immunology ; Helicobacter Infections - microbiology ; Helicobacter pylori - isolation & purification ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Infections ; Male ; Metformin - administration & dosage ; Metformin - adverse effects ; Multivariate analysis ; Predictive Value of Tests ; Prevalence ; Treatment Outcome ; Triglycerides ; Ulcers</subject><ispartof>Diabetes technology & therapeutics, 2015-02, Vol.17 (2), p.128-133</ispartof><rights>(©) Copyright 2015, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-836663709f8ff834f809d05c628ac74971ac41c1228d885833053c34456697d93</citedby><cites>FETCH-LOGICAL-c321t-836663709f8ff834f809d05c628ac74971ac41c1228d885833053c34456697d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25391019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Yuxin</creatorcontrib><creatorcontrib>Sun, Jiao</creatorcontrib><creatorcontrib>Wang, Xingsi</creatorcontrib><creatorcontrib>Tao, Xiaoming</creatorcontrib><creatorcontrib>Wang, Haidong</creatorcontrib><creatorcontrib>Tan, Wen</creatorcontrib><title>Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus</title><title>Diabetes technology & therapeutics</title><addtitle>Diabetes Technol Ther</addtitle><description>This study assessed whether Helicobacter pylori infection could influence metformin tolerance in patients with type 2 diabetes mellitus.
Demographic, anthropometric, ultrasound, and laboratory data were obtained from 415 metformin-naive patients with diabetes. H. pylori infection was assessed based on the (13)C-labeled urea breath test ((13)C-UBT). The study duration was 4 weeks, and all subjects started metformin from 500 mg/day to 1,500 mg/day progressively. Gastrointestinal side effects were assessed each week, and the metformin doses were adjusted by the compliance. Gastrointestinal side effects were compared between H. pylori-positive and -negative groups.
According to the (13)C-UBT results, 220 patients were categorized as H. pylori negative versus 195 as H. pylori positive. At baseline, the scoring of gastrointestinal symptoms showed no statistical difference between the two groups. After 4 weeks, for gastrointestinal symptoms such as abdominal pain, nausea, bloating, and anorexia, the respective percentages in H. pylori-positive and -negative subjects were 44.6% versus 21.8% (P < 0.01), 20.0% versus 9.6% (P < 0.01), 47.7% versus 23.2% (P < 0.01), and 32.8% versus 12.3% (P < 0.01). The final metformin dose was 951.28 ± 661.1 mg in H. pylori-positive subjects, significantly less than that in H. pylori-negative subjects (1,209.09 ± 522.91 mg) (P < 0.01). On multivariate analysis, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol were the independent parameters associated with any gastrointestinal symptoms.
Patients with diabetes having H. pylori infection demonstrated more gastrointestinal side effects than those without H. pylori infection after taking metformin. Furthermore, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol are independent determinants of metformin's side effects.</description><subject>Body mass index</subject><subject>Breath Tests</subject><subject>China - epidemiology</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Gastrointestinal Tract - drug effects</subject><subject>Helicobacter Infections - immunology</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori - isolation & purification</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Infections</subject><subject>Male</subject><subject>Metformin - administration & dosage</subject><subject>Metformin - adverse effects</subject><subject>Multivariate analysis</subject><subject>Predictive Value of Tests</subject><subject>Prevalence</subject><subject>Treatment Outcome</subject><subject>Triglycerides</subject><subject>Ulcers</subject><issn>1520-9156</issn><issn>1557-8593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkD2P1TAQRS0EYj-gpEWWaGjymLFjxy7RCtiVVqKB2vJzJsKrJA62I_T-PX7sQkE1U5y5OnMZe4NwQDD2wxj9QQD2BxAgn7FLVGrojLLy-XkX0FlU-oJdlfIAAIMU-JJdCCUtAtpLRrc0x5COPlTKfDvNKUce14lCjWnlI4VMvlDhC9Up5SWuvKaZsl8DNY5vvkZaa-G_Yv3B62kjLnhzOlL9czTPse7lFXsx-bnQ66d5zb5__vTt5ra7__rl7ubjfReaV-2M1FrLAexkpsnIfjJgR1BBC-PD0NsBfegxoBBmNEYZKUHJIPteaW2H0cpr9v4xd8vp506luiWW0CT8SmkvDrUSvRagsaHv_kMf0p7XZudwMGZAVBYa1T1SIadSMk1uy3Hx-eQQ3Ll_13515_7duf_Gv31K3Y8Ljf_ov4XL37o5f5E</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Huang, Yuxin</creator><creator>Sun, Jiao</creator><creator>Wang, Xingsi</creator><creator>Tao, Xiaoming</creator><creator>Wang, Haidong</creator><creator>Tan, Wen</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201502</creationdate><title>Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus</title><author>Huang, Yuxin ; Sun, Jiao ; Wang, Xingsi ; Tao, Xiaoming ; Wang, Haidong ; Tan, Wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-836663709f8ff834f809d05c628ac74971ac41c1228d885833053c34456697d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Body mass index</topic><topic>Breath Tests</topic><topic>China - epidemiology</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Gastrointestinal Tract - drug effects</topic><topic>Helicobacter Infections - immunology</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori - isolation & purification</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Infections</topic><topic>Male</topic><topic>Metformin - administration & dosage</topic><topic>Metformin - adverse effects</topic><topic>Multivariate analysis</topic><topic>Predictive Value of Tests</topic><topic>Prevalence</topic><topic>Treatment Outcome</topic><topic>Triglycerides</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Yuxin</creatorcontrib><creatorcontrib>Sun, Jiao</creatorcontrib><creatorcontrib>Wang, Xingsi</creatorcontrib><creatorcontrib>Tao, Xiaoming</creatorcontrib><creatorcontrib>Wang, Haidong</creatorcontrib><creatorcontrib>Tan, Wen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes technology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Yuxin</au><au>Sun, Jiao</au><au>Wang, Xingsi</au><au>Tao, Xiaoming</au><au>Wang, Haidong</au><au>Tan, Wen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus</atitle><jtitle>Diabetes technology & therapeutics</jtitle><addtitle>Diabetes Technol Ther</addtitle><date>2015-02</date><risdate>2015</risdate><volume>17</volume><issue>2</issue><spage>128</spage><epage>133</epage><pages>128-133</pages><issn>1520-9156</issn><eissn>1557-8593</eissn><coden>DTTHFH</coden><abstract>This study assessed whether Helicobacter pylori infection could influence metformin tolerance in patients with type 2 diabetes mellitus.
Demographic, anthropometric, ultrasound, and laboratory data were obtained from 415 metformin-naive patients with diabetes. H. pylori infection was assessed based on the (13)C-labeled urea breath test ((13)C-UBT). The study duration was 4 weeks, and all subjects started metformin from 500 mg/day to 1,500 mg/day progressively. Gastrointestinal side effects were assessed each week, and the metformin doses were adjusted by the compliance. Gastrointestinal side effects were compared between H. pylori-positive and -negative groups.
According to the (13)C-UBT results, 220 patients were categorized as H. pylori negative versus 195 as H. pylori positive. At baseline, the scoring of gastrointestinal symptoms showed no statistical difference between the two groups. After 4 weeks, for gastrointestinal symptoms such as abdominal pain, nausea, bloating, and anorexia, the respective percentages in H. pylori-positive and -negative subjects were 44.6% versus 21.8% (P < 0.01), 20.0% versus 9.6% (P < 0.01), 47.7% versus 23.2% (P < 0.01), and 32.8% versus 12.3% (P < 0.01). The final metformin dose was 951.28 ± 661.1 mg in H. pylori-positive subjects, significantly less than that in H. pylori-negative subjects (1,209.09 ± 522.91 mg) (P < 0.01). On multivariate analysis, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol were the independent parameters associated with any gastrointestinal symptoms.
Patients with diabetes having H. pylori infection demonstrated more gastrointestinal side effects than those without H. pylori infection after taking metformin. Furthermore, female gender, H. pylori infection, body mass index, triglycerides, age, and low-density lipoprotein-cholesterol are independent determinants of metformin's side effects.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>25391019</pmid><doi>10.1089/dia.2014.0203</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-9156 |
| ispartof | Diabetes technology & therapeutics, 2015-02, Vol.17 (2), p.128-133 |
| issn | 1520-9156 1557-8593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1652462061 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Body mass index Breath Tests China - epidemiology Diabetes Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Female Gastrointestinal Tract - drug effects Helicobacter Infections - immunology Helicobacter Infections - microbiology Helicobacter pylori - isolation & purification Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Infections Male Metformin - administration & dosage Metformin - adverse effects Multivariate analysis Predictive Value of Tests Prevalence Treatment Outcome Triglycerides Ulcers |
| title | Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T14%3A21%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Helicobacter%20pylori%20infection%20decreases%20metformin%20tolerance%20in%20patients%20with%20type%202%20diabetes%20mellitus&rft.jtitle=Diabetes%20technology%20&%20therapeutics&rft.au=Huang,%20Yuxin&rft.date=2015-02&rft.volume=17&rft.issue=2&rft.spage=128&rft.epage=133&rft.pages=128-133&rft.issn=1520-9156&rft.eissn=1557-8593&rft.coden=DTTHFH&rft_id=info:doi/10.1089/dia.2014.0203&rft_dat=%3Cproquest_cross%3E1652462061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1788711590&rft_id=info:pmid/25391019&rfr_iscdi=true |